Jakafi 5 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FTKPA
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,147
Award facts
- Contract value 100% obligated
- $12,146.79 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $12,146.79 by the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of Jakafi 5 mg tablets (60-count). This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis leveraging its established capabilities as a federal pharmaceutical supplier. The award represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at $499,999,999 and valid through November 2026.
The DLA SPE2DB Indefinite Delivery Contract establishes DMS Pharmaceutical Group as a critical vendor within the federal pharmaceutical supply chain, authorizing the issuance of firm fixed-price delivery orders for a comprehensive range of pharmaceutical products supporting Department of Defense healthcare facilities worldwide. This contract vehicle enables efficient procurement of prescription medications, biologics, over-the-counter products, and medical consumables to military health installations. The current delivery order for Jakafi, a prescription medication for the treatment of myelofibrosis and polycythemia vera, exemplifies the specialized pharmaceutical products distributed through this arrangement to support the medical supply needs of the defense healthcare system.
Quick answers
Who was awarded contract SPE2DB25FTKPA?
SPE2DB25FTKPA was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 21, 2025.
How much is contract SPE2DB25FTKPA worth?
The government has obligated $12,147 on SPE2DB25FTKPA.
Is contract SPE2DB25FTKPA an order under another contract?
Yes. SPE2DB25FTKPA is a delivery order under SPE2DB22D9112, an indefinite delivery contract.
Was contract SPE2DB25FTKPA competed?
The extent of competition for SPE2DB25FTKPA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award